On September 6, the standard review process in the ongoing trials of the vaccine candidate triggered a "voluntary pause to vaccination" across global sites so that independent committees and worldwide regulators could review safety data related to the vaccine, AstraZenecasaid.
In the USA, regulators are more hesitant to resume the trial, with the government-funded National Institutes of Health having now launched an investigation of its own, Kaiser Health News reported Monday.
The trial was suspended last week after a volunteer developed transverse myelitis, an inflammatory syndrome that affects the spinal cord.
"Clinical trials for the third phase are continuing under the strict supervision of medical teams, while following all measures to control the quality, safety and efficacy of the vaccine", said NCEMA. The experimental vaccine passed Phases I and II of clinical trials with 100% of volunteers generating antibodies after two doses in 28 days, an Abu Dhabi government statement said in July.
It declined to elaborate further on when other global trials were expected to restart.
It was announced on Monday by Abdul Rahman Al Owais, the Minister of Health and Prevention, that the findings from the recent clinical trial - which was officially recognised by the World Health Organisation - were promising.
At home, health experts have said that not everyone will need to be vaccinated. The World Health Organization (WHO) had flagged AstraZeneca's as the most promising.
Brazil has the third worst coronavirus outbreak after the United States and India and has become a sought-out testing ground for COVID-19 vaccines under development in Britain, China and Russian Federation.
AstraZeneca issued a statement on Tuesday night saying the late-stage studies of the vaccine had been paused while the company investigated whether a patient's reported side effects were connected to the vaccine.
We have already manufactured hundreds of thousands of doses. Sources told the news agency that enrollment of new patients and other trial procedures for the pivotal U.S. trial was being rescheduled until at least midweek and that it was not clear how long it would take for the FDA to complete its probe.